Different scenarios explaining the emergence of novel variants of concern (VOC) of the
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been reported …

The use of targeted biologic therapies for hematological malignancies has greatly expanded
in recent years. These agents act upon specific molecular pathways in order to target …

Extensive research in countries with high sociodemographic indices (SDIs) to date has
shown that coronavirus disease 2019 (COVID-19) may be directly associated with more …

Haemato‐oncological patients are at risk in case of severe acute respiratory syndrome
coronavirus‐2 (SARS‐CoV‐2) infection. Currently, vaccination is the best‐evaluated …

Tumor heterogeneity has been associated with immunotherapy and targeted drug
resistance in hepatocellular carcinoma (HCC). However, communications between tumor …

Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults. Despite its
indolent clinical course, therapy refractoriness and disease progression still represent an …

Acquired T-cell dysfunction is common in chronic B-cell malignancies. Given the strong
connection between T-cell metabolism and function, we investigated metabolic alterations …

Background: Chronic lymphocytic leukemia (CLL) is characterized by the clonal expansion
of malignant B-cells and multiple immune defects. This leads, among others, to severe …

Leukemia cells prevent immune system from clearing tumor cells by inducing the
immunosuppression of the bone marrow (BM) microenvironment. In recent years, further …

Immune-based therapeutic strategies have drastically changed the landscape of
hematological disorders, as they have introduced the concept of boosting immune …